Apotex Launches First Generic Version of Merck's Nasonex®
Mar 24, 2016Toronto, ON – Apotex Inc. announced today that it has launched the first generic version of Merck's Nasonex® nasal spray (mometasone furoate monohydrate) in the United States.
Apotex's mometasone furoate nasal spray is a once-daily anti-allergen indicated for treatment of nasal congestion. According to IMS Health, Nasonex® had approximately $955.5 million in sales in the 12 months ending January 2016.
"We are very pleased to make a more affordable version of this important allergy medicine available to the US public. Apotex is dedicated to bringing high quality versions of complex generic products to market, and we are delighted that these efforts will generate substantial savings for the US health care system," said Apotex Chief Executive Officer and President, Dr. Jeremy B. Desai. "The amount of work required by all stakeholders to enable the launch of a first generic of this complexity cannot be overstated, and we appreciate the role of everyone involved, including the FDA who provided steady guidance throughout the development process," Desai added.
FDA's approval of the company's generic version of Nasonex® follows Apotex's successful Hatch-Waxman challenge of US Patent No. 6,127,353 (the '353 patent), which Merck claimed covered the active ingredient. In June 2012, the US District Court for the District of New Jersey found that Apotex's product did not infringe the '353 patent. The decision was upheld in June 2013 by the Federal Circuit.
Apotex is the 7th largest generic pharmaceutical company globally (according to IMS Health) with over 8,000 employees and estimated sales of approximately $2 billion. The company's US headquarters is based in Weston, Florida. With its worldwide manufacturing sites, Apotex can produce up to 24 billion dosages per year. It produces 300 medicines in 4,000 dosages and formats that are exported to 115 countries. It has 500 products under development and will spend $2 billion over the next 10 years on research and development.
###
Jordan Berman
Global Director, Corporate Communications
Apotex Inc.
Direct: 416-401-7487
Mobile: 647-272-2287
Email
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
May 20, 2025
Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact
Apotex's 2024 Sustainability Report underscores our commitment to advancing health and unlocking new possibilities through partnerships, while championing sustainability and responsible business practices. "As we continue to execute our Journey of Health growth strategy, our focus on sustainability ensures that we are meeting the needs of patients, physicians, and pharmacists, and contributing positively to the environment and society. This report reflects our dedication to these values, and to transparency, accountability, and long-term value creation," said Allan Oberman, President & CEO, Apotex.
-
May 13, 2025
Apotex announces grant to Foundation for Mother and Child Health to promote maternal health with CAD $100,000 in annual funding
Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, yesterday announced a grant through the Apotex Global Health Access Fund to the Foundation for Mother and Child Health ("FMCH") in Mumbai, India to support programs that promote maternal health and address child malnutrition.
-
May 13, 2025
Apotex announces $100,000 in annual funding to advance maternal and infant health in Mexico
Mexico City - Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced a grant through the Apotex Global Health Access Fund to Vida y Familia México, I.A.P. ("VIFAC") to support programs that promote maternal and child health and address health disparities.